Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after Hematopoietic Stem Cell Transplan- tation

  • Published 2008


Objective: To evaluate the potential advantages of imipenem/cilastatin in control of fever in neutropenic HSCT recipients. Patients and Method: In this single-center study, 111 consecutive febrile episodes in 104 neutropenic HSCT recipients with a mean age of 26 years were randomized to treatment either with Imipenem/cilastatin 1 g, IV, q8h or cefepime (our… (More)


3 Figures and Tables

Slides referencing similar topics